A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Trial Profile

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Burtomab I 131 (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Sponsors Y-mAbs Therapeutics
  • Most Recent Events

    • 13 Oct 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.
    • 11 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top